The treatment of patients with mild to moderate Alzheimer's
(tyrosine kinase inhibitor)
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first human phase 2 study of masitinib carried-out in the treatment of Alzheimer's disease. Entitled, ˜Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial', this article is freely accessible online from BioMed Central's peer-reviewed journal Alzheimer's Research and Therapy. This randomized placebo-controlled phase 2 trial, conducted by Professor François Piette (Hôpital Charles-Foix in Ivry-sur-Seine) and colleagues from 12 study centers across France, investigated the hypothesis that masitinib's targeted inhibitory action on mast cells may reduce the symptoms of Alzheimer's disease. A total of 35 patients were included in this study. Neuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of the inflammatory network and participate in the regulation of the blood-brain barrier's permeability. Masitinib, a selective oral tyrosine kinase inhibitor, effectively inhibits the survival, migration and activity of mast cells. A prospective, multicentre, randomized, controlled, double-blind, parallel-group, phase 3 study to compare the efficacy and safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with mild to moderate Alzheimer's disease over a 24 week duration. A total of 300 patients will be enrolled with masitinib being administered orally as an add-on therapy to standard care. Read more: drugs.com
New analysis slams calcium supplements over heart problems
Researchers have warned that the indiscriminate use of calcium supplements ‘should be abandoned’, as a meta-analysis of 29,000 people suggests the risks of heart problems outweigh the potential benefits. Read more: nutraingredients.com
No comments:
Post a Comment